Literature DB >> 17498990

Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water.

Phanourios Tamamis1, Spiros S Skourtis, Dimitrios Morikis, John D Lambris, Georgios Archontis.   

Abstract

The cyclic 13-residue peptide compstatin is a potential therapeutic agent against the unregulated activation of the complement system. A thorough knowledge of its structural and dynamical properties in solution may assist the design of improved complement inhibitors. NMR studies have suggested that the 5-8 segment of free compstatin folds into a critical for activity 5-8 beta turn and the rest of the peptide is mainly disordered. Earlier computational studies of compstatin analogues with a polar-hydrogen/generalized-Born approximation reproduced the 5-8 turn, but also indicated the formation of beta-hairpin or alpha-helical elements and the existence of interactions between certain charged or aromatic sidechains. However, these features are absent or partly present in the NMR spectra, due to extensive conformational averaging. In order to check the compstatin properties with a more rigorous model of the intra- and intermolecular interactions, we conduct here 98-ns all-atom/explicit-water simulations of three compstatin analogues with variable activity; a native analogue, the more active mutant V4W/H9A and the inactive mutant Q5G. The 5-8 beta-turn population is in good accord with NMR. For the systems studied here, the simulations suggest that the 5-8 turn population does not correlate strictly with activity, in agreement with earlier mutational studies. Furthermore, they show structural differences among the analogues outside the 5-8 region. The possible role of these differences in activity is discussed. The probability of beta-hairpin or alpha-helix elements is much smaller with respect to the polar-hydrogen/GB simulations, and the persistent Trp4-Trp7 or Asp6-Arg11 sidechain interactions of the earlier GB studies are not reproduced. The present simulations extend the NMR data and improve our understanding of the properties of compstatin and related analogues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498990     DOI: 10.1016/j.jmgm.2007.03.014

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  8 in total

1.  New compstatin variants through two de novo protein design frameworks.

Authors:  M L Bellows; H K Fung; M S Taylor; C A Floudas; A López de Victoria; D Morikis
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

Review 2.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.

Authors:  Phanourios Tamamis; Panayiota Pierou; Chrystalla Mytidou; Christodoulos A Floudas; Dimitrios Morikis; Georgios Archontis
Journal:  Proteins       Date:  2011-08-30

4.  Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures.

Authors:  Ronald D Gorham; David L Forest; Phanourios Tamamis; Aliana López de Victoria; Márta Kraszni; Chris A Kieslich; Christopher D Banna; Meghan L Bellows-Peterson; Cynthia K Larive; Christodoulos A Floudas; Georgios Archontis; Lincoln V Johnson; Dimitrios Morikis
Journal:  Exp Eye Res       Date:  2013-08-15       Impact factor: 3.467

5.  Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations.

Authors:  Phanourios Tamamis; Dimitrios Morikis; Christodoulos A Floudas; Georgios Archontis
Journal:  Proteins       Date:  2010-09

6.  Molecular dynamics in drug design: new generations of compstatin analogs.

Authors:  Phanourios Tamamis; Aliana López de Victoria; Ronald D Gorham; Meghan L Bellows-Peterson; Panayiota Pierou; Christodoulos A Floudas; Dimitrios Morikis; Georgios Archontis
Journal:  Chem Biol Drug Des       Date:  2012-02-09       Impact factor: 2.817

7.  Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.

Authors:  Hongchang Qu; Paola Magotti; Daniel Ricklin; Emilia L Wu; Ioannis Kourtzelis; You-Qiang Wu; Yiannis N Kaznessis; John D Lambris
Journal:  Mol Immunol       Date:  2010-11-09       Impact factor: 4.407

8.  Computational analysis of complement inhibitor compstatin using molecular dynamics.

Authors:  Didier Devaurs; Dinler A Antunes; Lydia E Kavraki
Journal:  J Mol Model       Date:  2020-08-12       Impact factor: 1.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.